ArticleRSC advances2026
Development and validation of an NBD-F-based fluorometric method for the determination of plasma kynurenine and its clinical relevance in essential hypertension.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kynurenine pathway, the main route of tryptophan catabolism, contributes to the pathogenesis of essential hypertension by promoting immune activation and endothelial dysfunction. Within cardiovascular disease, kynurenine (KYN) acts both as a diagnostic biomarker and as a mechanistic mediator. This study aimed to develop a sensitive fluorometric method for plasma KYN determination evaluating its clinical relevance in hypertensive cohorts. Because native KYN exhibits weak intrinsic fluorescence, derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) was employed to generate a highly fluorescent derivative with enhanced spectroscopic properties, thereby improving the sensitivity of fluorometric detection. The resulting KYN-NBD derivative was measured at excitation and emission wavelengths of 485 and 555 nm, respectively. The reaction produced a stable KYN-NBD complex with a quantum yield of 0.63 compared with 0.22 for underivatized KYN, markedly improving method sensitivity. Validation according to ICH guidelines demonstrated linearity over 100-800 ng mL
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.